Issue 5 - The Cancer Letter

<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

24

No.

5

May 25, 2001May 25, 2001

Free

DOWNLOAD THE PDF

Gleevec Produces 59% Response Rate In Gastrointestinal Stromal Tumors

Preoperative Chemo Doubles Survival In Locally Advanced Bladder Cancer

Gleevec Approval Sets Record For FDA Review: 73 Days

Advances Found In Treatment Of Aerodigestive Cancers

Silicone Implants Not Linked To Increased Risk Of Death

B-14 Trial: No Advantage To 10 Years Of Tamoxifen

NCI-Approved Clinical Trials Listed For April 2001

Recent Issues

Volume 52 | Issue 32 - August 14, 2026

Volume 52 | Issue 31 - August 07, 2026

Volume 52 | Issue 30 - July 31, 2026

Volume 52 | Issue 29 - July 24, 2026

Volume 52 | Issue 28 - July 17, 2026

Volume 52 | Issue 27 - July 10, 2026